Etoricoxib-induced erythema-multiforme-like eruption

Dermatology

Volumn 216, Issue 3, 2008, Pages 227-228

  Thirion, Laurence ^a   Nikkels, Arjen F ^a,b   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Drug reaction; Erythema multiforme like eruption; Etoricoxib

Indexed keywords

ACENOCOUMAROL; BETAHISTINE; CELECOXIB; ETORICOXIB; FLUVOXAMINE MALEATE; PRAZEPAM; PROTHIPENDYL;

AGED; ALLERGIC VASCULITIS; ARTICLE; CASE REPORT; CELL INFILTRATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED ERYTHEMA MULTIFORME; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOACUSIS; IMMUNOHISTOCHEMISTRY; INGUINAL PRURITUS; JOINT SWELLING; KERATINOCYTE; KNEE PAIN; MALE; OSTEOPOROSIS; POLYARTHRITIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; PUNCH BIOPSY;

AGED; ARTHRITIS; CYCLOOXYGENASE 2 INHIBITORS; DRUG ERUPTIONS; ERYTHEMA MULTIFORME; HUMANS; MALE; PYRIDINES; SKIN; SULFONES;

EID: 40949123510     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112930     Document Type: Article

References (11)

1. Woodfork KA, Dyke KV: Anti-inflammatory and antirheumatic drugs; in Craig DR, Stitzel RE (eds): Modern Pharmacology with Clinical Applications, ed 6. Philadelphia, Lippincott, Williams & Wilkins, 2004, pp 423-439.
2. Mandal SP: Etoricoxib - a new, potent and highly selective COX-2 inhibitor. JAMA India 2004;3:79-82.
3. Mahajan A, Sharma R: COX-2 selective nonsteroidal anti-inflammatory drugs: current status. J Assoc Physicians India 2005;53:200-204.
4. Sanchez-Borges M, Caballero-Fonseca F, Carpiles-Hulett A: Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154-158.
5. Quialte J, Delgado J, Sanez de San Pedro B, et al: Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004;93:360-364.
6. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-204.
7. Scheider F, Meziani F, Chartier C, Alt M, Jaeger A: Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-853.
8. Goeschke B, Braathen LR: Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology 2004;209:53-56.
9. Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA: Serious skin reactions and selective Cox-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006;29:687-696.
10. D'Martina S, Vesta KS, Ripley TL: Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39:854-862.
11. Leclercq P, Malaise MG: Le médicament du mois: etoricoxib (Arcoxia®). Rev Méd Liège 2004;59:345-349.